Skip to main content
SpringerLink
Log in

Haemostasis Abnormalities in Chronic Liver Failure

  • Chapter
  • First Online:
Chronic Liver Failure

Part of the book series: Clinical Gastroenterology ((CG))

Abstract

Chronic liver disease is characterized by a complex hemostatic defect which affects primary haemostasis (platelets–vessel wall interaction), coagulation (fibrinogen-to-fibrin conversion), and fibrinolysis (clot dissolution).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol 2008;15:473–80.

    Article  PubMed  Google Scholar 

  2. Rubin MH, Weston MJ, Langley PG, et al. Platelet function in chronic liver disease: relationship to disease severity. Dig Dis Sci 1979;24:197–202.

    Article  CAS  PubMed  Google Scholar 

  3. Ordinas A, Escolar G, Cirera I, et al. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology 1996;24:1137–42.

    Article  CAS  PubMed  Google Scholar 

  4. Thomas DP, Ream VJ, Stuart RK. Platelet aggregation in patients with Laennec’s cirrhosis of the liver. N Engl J Med 1967;276:1344–8.

    Article  CAS  PubMed  Google Scholar 

  5. Ballard HS, Marcus AJ. Platelet aggregation in portal cirrhosis. Arch Intern Med 1976;136:316–9.

    Article  CAS  PubMed  Google Scholar 

  6. Laffi G, La Villa G, Pinzani M, et al. Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gastroenterology 1986;90:274–82.

    CAS  PubMed  Google Scholar 

  7. Laffi G, Cominelli F, Ruggiero M, et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988;8:1620–6.

    Article  CAS  PubMed  Google Scholar 

  8. Laffi G, Daskalopoulos G, Kronborg I, et al. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology 1986;90:182–7.

    CAS  PubMed  Google Scholar 

  9. Laffi G, Marra F, Failli P, et al. Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. Gastroenterology 1993;105:148–56.

    CAS  PubMed  Google Scholar 

  10. Laffi G, Marra F, Gresele P, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992;103:641–6.

    CAS  PubMed  Google Scholar 

  11. Ordinas A, Maragall S, Castillo R, et al. A glycoprotein I defect in the platelets of three patients with severe cirrhosis of the liver. Thromb Res 1978;13:297–302.

    Article  CAS  PubMed  Google Scholar 

  12. Violi F, Leo R, Vezza E, et al. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation Abnormalities in Cirrhosis Study Group. J Hepatol 1994;20:531–6.

    Article  CAS  PubMed  Google Scholar 

  13. Boberg KM, Brosstad F, Egeland T, et al. Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? Thromb Haemost 1999;81:378–81.

    CAS  PubMed  Google Scholar 

  14. Mannucci PM. Desmopressin: an historical introduction. Haemophilia 2008;14(Suppl 1):1–4.

    CAS  PubMed  Google Scholar 

  15. Mannucci PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986;67:1148–53.

    CAS  PubMed  Google Scholar 

  16. Burroughs AK, Matthews K, Qadiri M, et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J 1985;291:1377–81.

    Article  CAS  Google Scholar 

  17. Cattaneo M, Tenconi PM, Alberca I, et al. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 1990;64:358–60.

    CAS  PubMed  Google Scholar 

  18. de Franchis R, Arcidiacono PG, Carpinelli L, et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatology 1993;18:1102–7.

    Google Scholar 

  19. Wong AY, Irwin MG, Hui TW, et al. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 2003;50:14–20.

    Article  PubMed  Google Scholar 

  20. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44:53–61.

    Article  CAS  PubMed  Google Scholar 

  21. Langley PG, Hughes RD, Williams R. Increased factor VIII complex in fulminant hepatic failure. Thromb Haemost 1985;54:693–6.

    CAS  PubMed  Google Scholar 

  22. Lombardi R, Mannucci PM, Seghatchian MJ, et al. Alterations of factor VIII von Willebrand factor in clinical conditions associated with an increase in its plasma concentration. Br J Haematol 198;49:61–8.

    Google Scholar 

  23. Fukuda Y, Nagura H, Imoto M, et al. Immunohistochemical studies on structural changes of the hepatic lobules in chronic liver diseases. Am J Gastroenterol 1986;81:1149–55.

    CAS  PubMed  Google Scholar 

  24. Hollestelle MJ, Geertzen HG, Straatsburg IH, et al. Factor VIII expression in liver disease. Thromb Haemost 2004;91:267–75.

    CAS  PubMed  Google Scholar 

  25. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009;137:2105–11.

    Google Scholar 

  26. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999;45(Suppl 4):IV1–11.

    Article  PubMed  Google Scholar 

  27. Tripodi A, Caldwell SH, Hoffman M, et al. The prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007;26:141–8.

    Article  CAS  PubMed  Google Scholar 

  28. Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. Br J Haematol 2009;147:77–82.

    Article  PubMed  Google Scholar 

  29. Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004;79:109–16.

    Article  PubMed  Google Scholar 

  30. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4–15.

    Article  CAS  PubMed  Google Scholar 

  31. Chantarangkul V, Clerici M, Bressi A, et al. Thrombin generation assessed as endogenous thrombin potential (ETP) in patients with hypo- or hyper-coagulability. Effects of phospholipids, tissue factor and residual platelets on the measurement performed in platelet-poor and platelet-rich plasma. Haematologica 2003;88:547–54.

    CAS  PubMed  Google Scholar 

  32. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005;41:553–8.

    Article  CAS  PubMed  Google Scholar 

  33. Bevers EM, Comfurius P, Zwaal RF. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev 1991;5:146–54.

    Article  CAS  PubMed  Google Scholar 

  34. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006;44:440–5.

    Article  CAS  PubMed  Google Scholar 

  35. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and haemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006;44:1039–46.

    Article  CAS  PubMed  Google Scholar 

  36. Tripodi A, Primignani M, Chantarangkul V, et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009;124:132–6.

    Article  CAS  PubMed  Google Scholar 

  37. Bosch J, Thabut D, Bendtsen F, et al for the European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004;127:1123–30.

    Article  CAS  PubMed  Google Scholar 

  38. Bosch J, Thabut D, Albillos A, et al for the International Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology 2008;47:1604–14.

    CAS  Google Scholar 

  39. Lodge JP, Jonas S, Jones RM, et al for the rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005;11:973–9.

    Article  PubMed  Google Scholar 

  40. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005;11:895–900.

    Article  PubMed  Google Scholar 

  41. Rockey DC, Caldwell SH, Goodman ZD, et al. American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009;49:1017–44.

    Article  PubMed  Google Scholar 

  42. Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006;101:1524–8.

    Article  PubMed  Google Scholar 

  43. Søgaard KK, Horváth-Puhó E, Grønbaek H, et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case–control study. Am J Gastroenterol 2009;104:96–101.

    Article  PubMed  Google Scholar 

  44. Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology 2008;47:1384–93.

    Article  CAS  PubMed  Google Scholar 

  45. Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985;89:279–86.

    CAS  PubMed  Google Scholar 

  46. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005;54:691–7.

    Article  CAS  PubMed  Google Scholar 

  47. Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000;31:345–8.

    Article  CAS  PubMed  Google Scholar 

  48. Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984;37:772–7.

    Article  CAS  PubMed  Google Scholar 

  49. Hersch SL, Kunelis T, Francio RB. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 1987;69:1315–9.

    CAS  PubMed  Google Scholar 

  50. Tran-Thang C, Fasel-Felley J, Pralong G, et al. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989;62:651–3.

    CAS  PubMed  Google Scholar 

  51. Marongiu F, Mamusa AM, Mameli C, et al. Alpha 2 antiplasmin and disseminated intravascular coagulation in liver cirrhosis. Thromb Res 1985;37:287–94.

    Article  CAS  PubMed  Google Scholar 

  52. Sinclair TS, Booth NA, Penman SM, et al. Protease inhibitors in liver disease. Scand J Gastroenterol 1988;23:620–4.

    Article  CAS  PubMed  Google Scholar 

  53. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001;85:667–70.

    PubMed  Google Scholar 

  54. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001;121:131–9.

    Article  CAS  PubMed  Google Scholar 

  55. Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003;38:230–7.

    Article  CAS  PubMed  Google Scholar 

  56. Senzolo M, Riddell A, Tuddenham E, et al. Endogenous heparinoids contribute to coagulopathy in patients with liver disease. J Hepatol 2008;48:371–2; author reply 372–3.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, IRCCS Ospedale Maggiore/Mangiagalli/Regina Elena Foundation and Università degli Studi di Milano, Via Pace 9, 20122, Milano, Italy

    Armando Tripodi

Authors
  1. Armando Tripodi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Armando Tripodi .

Editor information

Editors and Affiliations

  1. Liver Unit, Hospital Clinic, University of Barcelona, Villarroel 170, Barcelona, 08036, Spain

    Pere Ginès

  2. College of Medicine, Division of Gastroenterology and Hepatol, Mayo Clinic, 200 First St. S.W, Rochester, 55905, Minnesota, USA

    Patrick S. Kamath

  3. Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, 08036, Spain

    Vicente Arroyo

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Tripodi, A. (2011). Haemostasis Abnormalities in Chronic Liver Failure. In: Ginès, P., Kamath, P., Arroyo, V. (eds) Chronic Liver Failure. Clinical Gastroenterology. Humana Press. https://doi.org/10.1007/978-1-60761-866-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-866-9_14

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-865-2

  • Online ISBN: 978-1-60761-866-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation